The Role of the Family Practice Provider in the Diagnosis, Management, and Referral Evaluation (ID: i764a-1)

1.After participating in this activity, how confident are you in the management of patients with AS in your practice?(Required.)
2.How many years have you been in practice?(Required.)
3.How many patients with AS do you manage?(Required.)
4.Please select the option that best describes your practice setting.(Required.)
5.How committed are you to making changes in your practice based on your participation in this activity?(Required.)
6.Which of the following best describes the impact of this activity on your performance?(Required.)
7.Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.(Required.)
8.What barriers do you see to making changes in your practice?(Required.)
9.After participating in today’s activity, I am now able to:(Required.)
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Review the epidemiology, etiology, and signs/symptoms of ankylosing spondylitis
Recognize the role of family practice in the timely diagnosis of AS
Apply current guideline recommendations to the management of ankylosing spondylitis
Evaluate the latest data on the efficacy, safety, and dosing/administration of newly-approved biologic therapies for ankylosing spondylitis
10.M. Elaine Husni, MD MPH, effectively:(Required.)
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Presented the material
Avoided commercial bias
11.The content presented:(Required.)
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Enhanced my current knowledge base
Addressed my most pressing questions
Promoted improvements or quality in health care
Was scientifically rigorous and evidence based
Avoided commercial bias or influence
12.As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?
13.Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for AS or related disease states.
14.If you indicated that you perceived commercial bias or influence, please describe.
Privacy & Cookie Notice